From: CircRNAs: biogenesis, functions, and role in drug-resistant Tumours
Cancer type | circRNAs | Drug resistance | Resistance mechanisms | Dysregulation | Biomarker | Refs |
---|---|---|---|---|---|---|
LUAD | circPVT1 | CDDP/MTA | miR-145-5p/ABCC1 axis | Upregulated | Prognostic | [120] |
CDR1-AS | PTX/CDDP | EGFR/PI3K signalling pathway | Upregulated | Prognostic | [105] | |
SCLC | circESRP1 | CDDP/ADM/DT-PACE | miR-93-5p/Smad7/p21(CDKN1A) | Downregulated | Prognostic and Therapeutic targets | [121] |
NSCLC | circ_0002483 | PTX | miR-182-5p/Grb2、Foxo1、Foxo3 | Downregulated | Therapeutic targets | [122] |
circ_0076305 | CDDP | miR-296-5p/STAT3 | Upregulated | Therapeutic targets | [123] | |
circRNA_103762 | CDDP | CHOP | Upregulated | Therapeutic targets | [124] | |
hsa_circ_0001946 | CDDP | NER signalling pathway | Downregulated | Diagnosis and Prognostic | [125] | |
hsa_circ_0004015 | Gefitinib | miR1183-PDK1 axis | Upregulated | Therapeutic targets | [25] | |
Breast cancer | hsa_circ_0006528 | ADM | miR-7-5p/Raf_1 axis | Upregulated | Unknown | [113] |
circKDM4C | ADM | miR-548p/PBLD axis | Downregulated | Prognostic | [128] | |
circMTO1 | Monastrol | TRAF4/Eg5 pathway | Downregulated | Prognostic and Therapeutic targets | [129] | |
circAMOTL1 | PTX | AKT signalling pathway | Upregulated | Therapeutic targets | [130] | |
circ-ABCB10 | PTX | Let-7a-5p /DUSP7 axis | Upregulated | Therapeutic targets | [131] | |
Prostate cancer | circFoxo3 | DTX | Foxo3 | Downregulated | Prognostic and Therapeutic targets | [132] |
hsa_circ_0004870 | ENZ | RBM39 | Downregulated | Diagnosis and Prognostic | [134] | |
circRNA17 | ENZ | miR-181c-5p/ARv7 signalling pathway | Downregulated | Therapeutic targets | [135] | |
Gastric cancer | circPVT1 | PTX | miR-124-3p/ZEB1 | Upregulated | Therapeutic targets | [139] |
circFN1 | CDDP | miR-182-5p | Upregulated | Therapeutic targets | [106] | |
circAKT3 | CDDP | PI3K/AKT signalling pathway | Upregulated | Therapeutic targets | [140] | |
circCCDC66 | CDDP | miR-618 and releasing BCL2 | Upregulated | Therapeutic targets | [136] | |
circMTHFD2 | MTA | miR-124/MDR-1 | Upregulated | Drug targets | [141] | |
circ0001546 | OXA | ATM/Chk2/p53 | Downregulated | Diagnosis and Prognostic | [115] | |
circRACGAP1 | Apatinib | miR-3657/ATG7 axis | Upregulated | Therapeutic targets | [142] | |
Colorectal cancer | circ_0000338 | 5-FU/OXA | unknown | Upregulated | Drug targets | [143] |
CIRS-122 | Apatinib | miR-122-PKM2 | Upregulated | Therapeutic targets | [144] | |
hsa_circ_0007031 | 5-FU | miR-885-3p/AKT3 | Upregulated | Drug targets | [107] | |
hsa_circ_0000504 | 5-FU | miR-485-5p/STAT3/AKT3 | Upregulated | Drug targets | [107] | |
hsa_circ_0048234 | 5-FU | miR-671-5p/EGFR axis | Downregulated | Drug targets | [107] | |
hsa_circ_0079662 | OXA | hsa-miR-324-5p/ HOXA9/ TNF-α | Upregulated | Unknown | [145] | |
Osteosarcoma | circPVT1 | ADM/CDDP | unknown | Upregulated | Diagnosis and Prognostic | [24] |
circ-LARP4 | ADM/CDDP | miR-424 | Downregulated | Unknown | [116] | |
hsa_circ_001569 | CDDP | Wnt/β-catenin signalling pathway | Upregulated | Therapeutic targets | [149] | |
ESCC | circRNA_100367 | Radiation resistance | miR217/WNT3 | Upregulated | Therapeutic targets | [151] |
circITCH | Radiation resistance | Wnt/β signalling pathway | Downregulated | Therapeutic targets | [152] | |
circRNA_001275 | CDDP | miR-370-3p/ Wnt7a | Upregulated | Diagnosis and Therapeutic targets | [153] | |
Nasopharynx cancer | circCRIM1 | DTX | miR-422a/FOXQ1 | Upregulated | Prognostic and Therapeutic targets | [154] |
Bladder cancer | hsa_circ_0000285 | CDDP | miR-124 and miR-558 | Downregulated | Prognostic | [156] |
circRNA Cdr1as | CDDP | miR-1270/APAF1 | Upregulated | Therapeutic targets | [157] | |
Ovarian cancer | circRNA Cdr1as | CDDP | miR-1270/SCAI | Downregulated | Unknown | [158] |
circCELSR1 | PTX | miR-1252/FOXR2 | Upregulated | Therapeutic targets | [159] | |
AML | circPAN3 | ADM | circPAN3-miR-153-5p/miR-183-5p-XIAP axis or AMPK/mTOR pathway | Upregulated | Drug targets | |
circMYBL2 | quizartinib | FLT3-ITD signalling pathway | Upregulated | Therapeutic targets | [82] | |
f-circPR | Ara-C | p-AKT signalling | Upregulated | Diagnosis and Therapeutic targets | [36] | |
f-circM9 | Ara-C | MAPK and AKT1-induced signalling | Upregulated | Diagnosis and Therapeutic targets | [36] | |
CML | circ_0009910 | imatinib | miR-34a-5p/ ULK1-induced autophagy | Upregulated | Drug targets | [165] |
circBA9.3 | TKIs | BCR-ABL pathway | Upregulated | Therapeutic targets | [166] | |
circ_100053 | imatinib | BCR-ABL pathway | Upregulated | Diagnosis and Therapeutic targets | [168] | |
MM | hsa_circ_0007841 | BTZ | unknown | Upregulated | Diagnosis and Prognostic | [170] |
Pancreatic cancer | circHIPK3 | GEM | miR-330-5p/RASSF1 | Upregulated | Prognostic and Drug targets | [171] |
Cholangiocarcinoma | circ-SMARCA5 | CDDP/GEM | unknown | Downregulated | Prognostic | [172] |
HCC | circ_0003418 | CDDP | Wnt/β-catenin signaling pathway | Downregulated | Unknown | [173] |
Renal carcinoma | hsa_circ_0035483 | GEM | miR-335/CCNB1 | Upregulated | Unknown | [174] |
Glioblastoma | circNFIX | TMZ | miR-132 | Upregulated | Prognostic and Therapeutic targets | [175] |